Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

2.63
+0.09503.75%
Post-market: 2.660.0300+1.14%19:30 EDT
Volume:3.46M
Turnover:9.06M
Market Cap:288.71M
PE:-15.47
High:2.78
Open:2.78
Low:2.52
Close:2.54
52wk High:5.45
52wk Low:2.42
Shares:109.77M
Float Shares:85.39M
Volume Ratio:1.70
T/O Rate:4.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:0.78
PE(LYR):-1.31

Loading ...

Lexeo Therapeutics to Join Fireside Chat at Chardan Healthcare Conference

Reuters
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and Chemed (CHE)

TIPRANKS
·
Yesterday

Rocket Pharma Outlines FDA-Aligned Pivotal Phase 2 Trial Path for Danon Gene Therapy RP-A501

Reuters
·
Oct 07

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for Rp-A501 Following Danon Disease Investor Webinar

THOMSON REUTERS
·
Oct 07

Rocket Pharmaceuticals Price Target Maintained with a $11.00/Share by Chardan Capital

Dow Jones
·
Oct 07

Cantor Fitzgerald Remains a Buy on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Oct 07

Rocket Pharmaceuticals, Inc. : Jefferies Cuts Target Price to $2.95 from $4.25

THOMSON REUTERS
·
Oct 07

Rocket Secures Credit Facility From Hercules Capital

MT Newswires Live
·
Oct 07

Rocket Pharmaceuticals Secures Strategic Credit Facility for up to $150 Million from Hercules Capital

THOMSON REUTERS
·
Oct 07

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Oct 03

Rocket Pharmaceuticals Shares Rise After Needham Upgrade

MT Newswires Live
·
Sep 17

Needham Upgrades Rocket Pharmaceuticals to Buy From Hold, Price Target is $9

MT Newswires Live
·
Sep 16

Rocket Pharmaceuticals upgraded to Buy from Hold at Needham

TIPRANKS
·
Sep 16

Rocket Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Sep 15

Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial

Dow Jones
·
Sep 15

Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial

MT Newswires Live
·
Sep 15

Rocket Pharmaceuticals, - FDA Confirms 12-Month Co-Primary Endpoints for Potential Accelerated Approval

THOMSON REUTERS
·
Sep 15

Rocket Pharmaceuticals, - Expects to Complete Rp-A501 Dosing by Mid-2027

THOMSON REUTERS
·
Sep 15

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of Rp-A501 in Danon Disease

THOMSON REUTERS
·
Sep 15

Rocket Pharmaceuticals, - FDA Confirms Pivotal Efficacy Population of 12 Patients for Rp-A501 Trial

THOMSON REUTERS
·
Sep 15